Arcus Biosciences (RCUS) Competitors $7.16 -0.73 (-9.28%) Closing price 03:58 PM EasternExtended Trading$7.48 +0.32 (+4.43%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. RARE, SWTX, AKRO, ALVO, RYTM, MRUS, CRNX, IMVT, VKTX, and PTGXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Rhythm Pharmaceuticals (RYTM), Merus (MRUS), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Ultragenyx Pharmaceutical SpringWorks Therapeutics Akero Therapeutics Alvotech Rhythm Pharmaceuticals Merus Crinetics Pharmaceuticals Immunovant Viking Therapeutics Protagonist Therapeutics Ultragenyx Pharmaceutical (NASDAQ:RARE) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Does the MarketBeat Community favor RARE or RCUS? Ultragenyx Pharmaceutical received 642 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote while only 65.33% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformUltragenyx PharmaceuticalOutperform Votes83877.52% Underperform Votes24322.48% Arcus BiosciencesOutperform Votes19665.33% Underperform Votes10434.67% Do insiders & institutionals have more ownership in RARE or RCUS? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 5.8% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 12.3% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate RARE or RCUS? Ultragenyx Pharmaceutical presently has a consensus price target of $92.79, suggesting a potential upside of 164.12%. Arcus Biosciences has a consensus price target of $30.25, suggesting a potential upside of 322.60%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Ultragenyx Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is RARE or RCUS more profitable? Ultragenyx Pharmaceutical has a net margin of -101.60% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-101.60% -193.80% -38.15% Arcus Biosciences -102.66%-45.59%-22.38% Which has preferable valuation and earnings, RARE or RCUS? Arcus Biosciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.89-$569.18M-$6.34-5.54Arcus Biosciences$258M2.92-$307M-$3.10-2.31 Which has more risk & volatility, RARE or RCUS? Ultragenyx Pharmaceutical has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Does the media refer more to RARE or RCUS? In the previous week, Ultragenyx Pharmaceutical had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 3 mentions for Arcus Biosciences. Ultragenyx Pharmaceutical's average media sentiment score of 0.92 beat Arcus Biosciences' score of -0.01 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryArcus Biosciences beats Ultragenyx Pharmaceutical on 10 of the 19 factors compared between the two stocks. Remove Ads Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$829.54M$6.73B$5.54B$18.89BDividend YieldN/A2.79%5.35%3.79%P/E Ratio-2.276.9923.2531.43Price / Sales2.92198.60361.2625.45Price / CashN/A65.6738.1617.54Price / Book1.165.926.494.36Net Income-$307M$142.37M$3.21B$1.02B7 Day Performance-15.53%-9.32%-6.42%-5.42%1 Month Performance-32.02%-10.26%-0.68%-5.81%1 Year Performance-59.54%-15.08%6.05%-0.44% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.2292 of 5 stars$7.16-9.3%$30.25+322.6%-55.5%$829.54M$258M-2.27500Gap DownHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3568 of 5 stars$39.36+0.5%$91.71+133.0%-24.1%$3.64B$560.23M-6.211,276News CoveragePositive NewsGap DownSWTXSpringWorks Therapeutics1.9706 of 5 stars$48.51-2.8%$73.20+50.9%+0.5%$3.64B$191.59M-13.94230Positive NewsGap DownAKROAkero Therapeutics4.1424 of 5 stars$45.08-0.3%$76.29+69.2%+79.4%$3.59BN/A-12.0230Positive NewsGap DownALVOAlvotech1.8758 of 5 stars$11.56-0.1%$18.00+55.7%-19.4%$3.49B$391.87M-6.251,026RYTMRhythm Pharmaceuticals4.278 of 5 stars$53.72+3.2%$69.46+29.3%+29.7%$3.40B$130.13M-12.41140Gap DownMRUSMerus2.3026 of 5 stars$48.77+3.2%$85.31+74.9%-4.8%$3.37B$36.13M-12.3537CRNXCrinetics Pharmaceuticals4.3984 of 5 stars$35.94+4.4%$74.30+106.7%-31.8%$3.34B$1.04M-9.64210News CoverageIMVTImmunovant2.4393 of 5 stars$19.44-1.0%$41.70+114.5%-46.7%$3.30BN/A-7.42120Positive NewsGap DownVKTXViking Therapeutics4.3531 of 5 stars$29.28+1.1%$97.67+233.6%-66.8%$3.29BN/A-29.2820Options VolumePTGXProtagonist Therapeutics3.5052 of 5 stars$52.53-0.2%$62.56+19.1%+72.2%$3.22B$434.43M19.75120Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors SpringWorks Therapeutics Competitors Akero Therapeutics Competitors Alvotech Competitors Rhythm Pharmaceuticals Competitors Merus Competitors Crinetics Pharmaceuticals Competitors Immunovant Competitors Viking Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCUS Stock Free RCUS Stock Alerts